Table 2.
Clinical course of patients with pituitary AI.
| ICI class | ICI | n | AI (n) | AI for each ICI class (n) | Day of pre-onset visit (d) | Day of symptom onset (d) | Day of diagnosis of AI (d) |
|---|---|---|---|---|---|---|---|
| PD-1 | Niv | 216 | 5 | 13 (3.4%) | 164 | 184 | 198 |
| Pem | 164 | 8 | |||||
| Niv > Pem | 2 | 0 | |||||
| PD-L1 | Atez | 60 | 0 | 1 (1.0%) | 5 | 33 | 72 |
| Avel | 7 | 0 | |||||
| Dur | 29 | 1 | |||||
| Dur > Atez | 1 | 0 | |||||
| PD-1 > PD-L1 | Niv > Atez | 1 | 0 | 0 (0.0%) | 0 | 0 | 0 |
| Pem > Atez | 1 | 0 | |||||
| CTLA-4 or CTLA-4 + PD-1 | Ipi or Ipi + PD-1 | 44 | 5 | 5 (11.4%) | 62 | 64 | 83 |
A > B indicates change of ICI from A to B. ‘Day’ is the median number of days from the first administration of ICI.
Abbreviation: AI adrenal insufficiency, Atez atezolizumab, Avel avelumab, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, Dur durvalumab, ICI immune checkpoint inhibitor, Ipi ipilimumab, Niv nivolumab, PD-1 programmed cell death-1, PD-L1 programmed death-ligand 1, Pem pembrolizumab.